Sei Investments Co. Sells 279,140 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Sei Investments Co. lessened its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 85.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 48,683 shares of the company's stock after selling 279,140 shares during the quarter. Sei Investments Co. owned approximately 0.10% of Pacira BioSciences worth $1,393,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC grew its stake in Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company's stock valued at $38,000 after purchasing an additional 932 shares in the last quarter. Park Place Capital Corp bought a new position in Pacira BioSciences in the second quarter valued at approximately $46,000. Innealta Capital LLC bought a new position in Pacira BioSciences in the second quarter valued at approximately $50,000. nVerses Capital LLC grew its stake in Pacira BioSciences by 800.0% in the second quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock valued at $51,000 after purchasing an additional 1,600 shares in the last quarter. Finally, Natixis bought a new position in shares of Pacira BioSciences during the 1st quarter worth approximately $95,000. Institutional investors and hedge funds own 99.73% of the company's stock.

Pacira BioSciences Trading Down 3.2 %

Shares of Pacira BioSciences stock traded down $0.53 on Monday, hitting $15.98. 257,045 shares of the company's stock traded hands, compared to its average volume of 899,296. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $35.95. The company has a debt-to-equity ratio of 0.67, a current ratio of 6.82 and a quick ratio of 5.70. The company has a fifty day moving average of $15.40 and a two-hundred day moving average of $22.88. The company has a market capitalization of $737.16 million, a price-to-earnings ratio of 11.17 and a beta of 0.84.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its earnings results on Tuesday, July 30th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.53 by $0.11. Pacira BioSciences had a return on equity of 13.22% and a net margin of 9.21%. The company had revenue of $178.02 million for the quarter, compared to analyst estimates of $173.31 million. As a group, sell-side analysts expect that Pacira BioSciences, Inc. will post 2.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PCRX. JPMorgan Chase & Co. restated an "underweight" rating and issued a $10.00 price target (down from $45.00) on shares of Pacira BioSciences in a research note on Monday, August 12th. StockNews.com cut Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a report on Monday, August 12th. Barclays cut Pacira BioSciences from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $38.00 to $25.00 in a report on Wednesday, July 3rd. Royal Bank of Canada boosted their price target on Pacira BioSciences from $14.00 to $15.00 and gave the stock a "sector perform" rating in a report on Friday. Finally, Piper Sandler cut Pacira BioSciences from an "overweight" rating to a "neutral" rating and lowered their price target for the stock from $42.00 to $11.00 in a report on Monday, August 12th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Pacira BioSciences has a consensus rating of "Hold" and an average price target of $24.20.

Insider Transactions at Pacira BioSciences

In other Pacira BioSciences news, CEO Frank D. Lee purchased 8,264 shares of the firm's stock in a transaction that occurred on Monday, August 12th. The stock was bought at an average cost of $12.10 per share, with a total value of $99,994.40. Following the completion of the transaction, the chief executive officer now owns 107,784 shares of the company's stock, valued at $1,304,186.40. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders purchased a total of 11,176 shares of company stock valued at $136,240 over the last ninety days. 6.40% of the stock is currently owned by insiders.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.